Summary

Market Overview
The Global Pancreatic Cancer Diagnostics Market is anticipated to expand from USD 3.01 Billion in 2025 to USD 4.59 Billion by 2031, reflecting a 7.29% CAGR, and encompasses a variety of medical tests such as biomarker assays, molecular diagnostics, biopsy techniques, and advanced imaging. Growth is primarily stimulated by the increasing worldwide prevalence of the disease, its severe mortality rates, the challenges associated with early detection, and a rising need for sophisticated tools like AI-enhanced imaging and non-invasive liquid biopsies. Highlighting the critical demand for better diagnostic solutions, the American Cancer Society projects that 67,440 people in the U.S. will be diagnosed with pancreatic cancer in 2025. However, market growth continues to be hindered by the steep costs and restricted availability of these cutting-edge technologies in certain areas, which often postpones essential patient treatment.
Market Driver
A major catalyst for the expansion of the diagnostics market is the increasing global rate of pancreatic cancer, which drives the need for more accessible and efficient diagnostic instruments to catch the disease early and enhance patient prognosis. The continuous rise in cases emphasizes the critical need to identify this highly fatal cancer at more manageable stages, as noted in a January 2026 report by the Lustgarten Foundation citing the American Cancer Society, which highlighted a roughly 1% annual incidence increase since the 1990s. Simultaneously, breakthroughs in diagnostic methods, including artificial intelligence, advanced imaging, and liquid biopsies, are profoundly shaping the market by providing more accurate and less invasive staging and detection options. Collaborative efforts and funding are further accelerating this progress, exemplified by NVIDIA's August 2025 partnership with 12 global institutions to build a comprehensive pancreatic CT dataset, and AIM ImmunoTech's April 2026 rights offering that secured around $1.8 million for metastatic pancreatic cancer research.
Market Challenge
The expansion of the Global Pancreatic Cancer Diagnostics Market is significantly hindered by the high costs and limited availability of cutting-edge diagnostic tools. The substantial financial investment needed to purchase and upkeep sophisticated imaging systems, molecular platforms, and complex biomarker assays limits their integration, especially within budget-restricted healthcare networks and developing regions, thereby reducing testing volumes and slowing overall market progress. Additionally, this lack of widespread access to specialized technologies directly compromises patient outcomes by delaying crucial diagnoses. The Lustgarten Foundation, referencing the American Cancer Society's 2026 report, noted that a mere 17% of patients receive a diagnosis at a localized, highly treatable stage, underscoring a major shortfall in the application of advanced diagnostic resources as financial barriers and unequal access continue to restrict the market's reach and growth potential.
Market Trends
The Global pancreatic cancer diagnostics market is being heavily shaped by next-generation sequencing and advanced molecular profiling, which provide a profound understanding of tumor biology to help tailor personalized treatment plans. The growing accessibility and expanding reimbursement options for these sophisticated tests are encouraging broader clinical use, as seen in January 2026 when Illumina's FDA-approved TruSight test secured CMS reimbursement at $2,989.55, smoothing the path for Medicare patients and boosting market integration. Concurrently, the rise of multi-cancer early detection systems represents a crucial shift toward proactive screening, allowing for the identification of pancreatic and other cancers in individuals without symptoms. Innovations like Guardant Health's Shield blood test, which achieved a 68% sensitivity rate for pancreatic cancer in a June 2025 study and earned FDA Breakthrough Device status, are vital for expanding the diagnostic market and improving early detection for this notoriously late-diagnosed disease.

Key Market Players
* Siemens Healthineers AG
* Myriad Genetics, Inc.
* Pfizer, Inc
* Novartis AG
* AstraZeneca plc
* Immunovia AB
* Laboratory Corporation of America Holdings
* Abbott Laboratories
* Agilent Technologies, Inc.
* Thermo Fisher Scientific Inc.

Report Scope
In this report, the Global Pancreatic Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

# Pancreatic Cancer Diagnostics Market, By Test Type {Diagnostic Imaging Tests
* CT scan
* MRI
* Ultrasound
* Others
# Pancreatic Cancer Diagnostics Market, By Cancer Type
* Exocrine
* Adenocarcinoma
* Squamous Cell Carcinoma
* Colloid Carcinoma
* Others
# Pancreatic Cancer Diagnostics Market, By End User
* Hospitals & Clinics
* Diagnostic Centers
* Others
# Pancreatic Cancer Diagnostics Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Pancreatic Cancer Diagnostics Market.
Available Customizations:
Global Pancreatic Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Pancreatic Cancer Diagnostics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Test Type {Diagnostic Imaging Tests (CT scan, MRI, Ultrasound, Others)
5.2.2. By Cancer Type (Exocrine, Adenocarcinoma, Squamous Cell Carcinoma, Colloid Carcinoma, Others)
5.2.3. By End User (Hospitals & Clinics, Diagnostic Centers, Others)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. North America Pancreatic Cancer Diagnostics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Test Type {Diagnostic Imaging Tests
6.2.2. By Cancer Type
6.2.3. By End User
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Pancreatic Cancer Diagnostics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Test Type {Diagnostic Imaging Tests
6.3.1.2.2. By Cancer Type
6.3.1.2.3. By End User
6.3.2. Canada Pancreatic Cancer Diagnostics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Test Type {Diagnostic Imaging Tests
6.3.2.2.2. By Cancer Type
6.3.2.2.3. By End User
6.3.3. Mexico Pancreatic Cancer Diagnostics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Test Type {Diagnostic Imaging Tests
6.3.3.2.2. By Cancer Type
6.3.3.2.3. By End User
7. Europe Pancreatic Cancer Diagnostics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Test Type {Diagnostic Imaging Tests
7.2.2. By Cancer Type
7.2.3. By End User
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Pancreatic Cancer Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Test Type {Diagnostic Imaging Tests
7.3.1.2.2. By Cancer Type
7.3.1.2.3. By End User
7.3.2. France Pancreatic Cancer Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Test Type {Diagnostic Imaging Tests
7.3.2.2.2. By Cancer Type
7.3.2.2.3. By End User
7.3.3. United Kingdom Pancreatic Cancer Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Test Type {Diagnostic Imaging Tests
7.3.3.2.2. By Cancer Type
7.3.3.2.3. By End User
7.3.4. Italy Pancreatic Cancer Diagnostics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Test Type {Diagnostic Imaging Tests
7.3.4.2.2. By Cancer Type
7.3.4.2.3. By End User
7.3.5. Spain Pancreatic Cancer Diagnostics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Test Type {Diagnostic Imaging Tests
7.3.5.2.2. By Cancer Type
7.3.5.2.3. By End User
8. Asia Pacific Pancreatic Cancer Diagnostics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Test Type {Diagnostic Imaging Tests
8.2.2. By Cancer Type
8.2.3. By End User
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Pancreatic Cancer Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Test Type {Diagnostic Imaging Tests
8.3.1.2.2. By Cancer Type
8.3.1.2.3. By End User
8.3.2. India Pancreatic Cancer Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Test Type {Diagnostic Imaging Tests
8.3.2.2.2. By Cancer Type
8.3.2.2.3. By End User
8.3.3. Japan Pancreatic Cancer Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Test Type {Diagnostic Imaging Tests
8.3.3.2.2. By Cancer Type
8.3.3.2.3. By End User
8.3.4. South Korea Pancreatic Cancer Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Test Type {Diagnostic Imaging Tests
8.3.4.2.2. By Cancer Type
8.3.4.2.3. By End User
8.3.5. Australia Pancreatic Cancer Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Test Type {Diagnostic Imaging Tests
8.3.5.2.2. By Cancer Type
8.3.5.2.3. By End User
9. Middle East & Africa Pancreatic Cancer Diagnostics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Test Type {Diagnostic Imaging Tests
9.2.2. By Cancer Type
9.2.3. By End User
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Pancreatic Cancer Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Test Type {Diagnostic Imaging Tests
9.3.1.2.2. By Cancer Type
9.3.1.2.3. By End User
9.3.2. UAE Pancreatic Cancer Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Test Type {Diagnostic Imaging Tests
9.3.2.2.2. By Cancer Type
9.3.2.2.3. By End User
9.3.3. South Africa Pancreatic Cancer Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Test Type {Diagnostic Imaging Tests
9.3.3.2.2. By Cancer Type
9.3.3.2.3. By End User
10. South America Pancreatic Cancer Diagnostics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Test Type {Diagnostic Imaging Tests
10.2.2. By Cancer Type
10.2.3. By End User
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Pancreatic Cancer Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Test Type {Diagnostic Imaging Tests
10.3.1.2.2. By Cancer Type
10.3.1.2.3. By End User
10.3.2. Colombia Pancreatic Cancer Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Test Type {Diagnostic Imaging Tests
10.3.2.2.2. By Cancer Type
10.3.2.2.3. By End User
10.3.3. Argentina Pancreatic Cancer Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Test Type {Diagnostic Imaging Tests
10.3.3.2.2. By Cancer Type
10.3.3.2.3. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Pancreatic Cancer Diagnostics Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Siemens Healthineers AG
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Myriad Genetics, Inc.
15.3. Pfizer, Inc
15.4. Novartis AG
15.5. AstraZeneca plc
15.6. Immunovia AB
15.7. Laboratory Corporation of America Holdings
15.8. Abbott Laboratories
15.9. Agilent Technologies, Inc.
15.10. Thermo Fisher Scientific Inc.
16. Strategic Recommendations
17. About Us & Disclaimer